enow.com Web Search

  1. Ads

    related to: breakthroughs in multiple myeloma
    • Expert Insights

      Get insights from experts in the

      field of multiple myeloma.

    • Request a Rep

      Complete a request form and have

      a rep reach out to you.

Search results

  1. Results from the WOW.Com Content Network
  2. Multiple myeloma - Wikipedia

    en.wikipedia.org/wiki/Multiple_myeloma

    Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. [6] Often, no symptoms are noticed initially. [10] As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. [10]

  3. C4 Therapeutics Presents Cemsidomide Phase 1 Data at the ...

    lite.aol.com/tech/story/0022/20241208/9315853.htm

    Down regulation of IRF4 promotes the death of both myeloma and lymphoma cells. About Multiple Myeloma Multiple myeloma (MM) is a rare blood cancer affecting plasma cells. Approximately 36,000 people in the United States are diagnosed with MM each year. Despite advances in treatment, multiple myeloma remains incurable.

  4. CARVYKTI® Significantly Improved Minimal Residual Disease ...

    lite.aol.com/tech/story/0022/20241209/9316602.htm

    “The latest MRD data showcases the advances of CARVYKTI and further demonstrates why it is a leading treatment for patients with multiple myeloma,” said Ying Huang, Ph. D., Chief Executive Officer of Legend Biotech.

  5. Talquetamab - Wikipedia

    en.wikipedia.org/wiki/Talquetamab

    In the United States, Janssen received breakthrough therapy designation for talquetamab in June 2022, for the treatment of adults with relapsed or refractory multiple myeloma, who have previously received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. [13]

  6. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    To treat relapsed or refractory multiple myeloma after at least four lines of therapy [1] Fabhalta: To treat paroxysmal nocturnal hemoglobinuria [1] Izervay: To treat geographic atrophy secondary to age-related macular degeneration [1] Leqembi: To treat Alzheimer's disease [1] Loqtorzi

  7. Sanofi wins US approval for multiple myeloma drug in newly ...

    www.aol.com/news/sanofi-wins-us-approval-drug...

    Sarclisa has previously been approved for use as a fallback therapy for certain cases of multiple myeloma after standard treatments have failed. The French drugmaker, a market leader in anti ...

  1. Ads

    related to: breakthroughs in multiple myeloma